


# Stabilis



## Amikacin sulfate



### Noms commerciaux

|           |  |
|-----------|--|
| Adnet     | Inde   |
| Agnicin   | Mexique  |
| Akamin    | Equateur   |
| Akim      | Equateur   |
| Amicacil  | Brésil   |
| Amicilon  | Brésil   |
| Amicin    | Malaisie   |
| Amicip    | Vénézuela  |
| Amijeksin | Turquie  |
| Amikabiot | Equateur, Pérou  |
| Amikacin  | Allemagne, Arabie Saoudite, Canada, Egypte, Etats Unis d'Amérique, Grande Bretagne, Iran, Malaisie, Nouvelle Zélande   |
| Amikacina | Argentine, Chili, Colombie, Equateur, Espagne, Italie, Mexique, Pérou, Vénézuela   |
| Amikacine | Belgique, France, Maroc, Pays bas  |
| Amikafur  | Mexique  |
| Amikagram | Pérou  |
| Amikalem  | Mexique  |
| Amikamed  | Pérou  |
| Amikamek  | Pérou  |
| Amikan    | Italie   |
| Amikavax  | Vénézuela  |
| Amikaver  | Turquie  |
| Amikayect | Mexique  |
| Amikem    | Pérou  |
| Amiketem  | Turquie  |
| Amikin    | Arabie Saoudite, Australie, Brésil, Colombie, Egypte, Equateur, Etats Unis d'Amérique, Grande Bretagne, Hongrie, Irlande, Mexique, Pérou, Pologne, Suisse, Tunisie |
| Amiklin   | France, Turquie  |
| Amikosit  | Roumanie, Tunisie, Turquie   |
| Amikram   | Pérou  |
| Amukin    | Belgique, Luxembourg, Pays bas   |
| Apalin    | Malaisie   |
| Baxi K    | Chili, Mexique   |
| Behcacin  | Inde, Vénézuela  |
| Belka     | Inde   |

|            |  |
|------------|--|
| Biclin     | Allemagne, Autriche, Espagne, Finlande, Mexique, Portugal, Suède |
| Biodacyna  | Pologne  |
| Biokacin   | Mexique  |
| Briklin    | Grèce  |
| Cadicin    | Inde   |
| Chemacin   | Italie   |
| Cikabit    | Inde   |
| Cinamica   | Inde   |
| Cinas      | Inde   |
| Consumonit | Grèce  |
| Domak      | Inde   |
| Doxocar    | Argentine  |
| Elcin      | Inde   |
| Elmik      | Inde   |
| Emcin      | Inde   |
| Emica      | Inde   |
| Farcyclin  | Grèce  |
| Flexelite  | Grèce  |
| Greini     | Argentine  |
| Ipacin     | Iran   |
| Itukacin   | Pérou  |
| Kancin     | Grèce  |
| Lanomycin  | Grèce  |
| Lukadin    | Italie   |
| Masmika    | Inde   |
| Mediamik   | Italie   |
| Micalpha   | Grèce  |
| Micigen    | Mexique  |
| Migracin   | Italie   |
| Mikacin    | Arabie Saoudite  |
| Nekacin    | Italie   |
| Novamin    | Brésil   |
| Orlobin    | Grèce  |
| Remikin    | Grèce  |
| Rovericlin | Grèce  |
| Uzix       | Grèce  |



## Stabilité des solutions

|  |           | 0,25 & 5 mg/ml | -15°C |  | 30 |  |  | 561 |
|--|-----------|----------------|-------|--|----|--|--|-----|
|  |           | 0,25 & 5 mg/ml | 25°C  |  | 24 |  |  | 561 |
|  |           | 0,25 & 5 mg/ml | 4°C   |  | 60 |  |  | 561 |
|  |           | 4 mg/ml        | 25°C  |  | 48 |  |  | 565 |
|  | <b>RL</b> | 0,25 & 5 mg/ml | -15°C |  | 30 |  |  | 561 |
|  | <b>RL</b> | 0,25 & 5 mg/ml | 25°C  |  | 24 |  |  | 561 |

|  |    |                 |           |  |    |  |  |      |
|--|----|-----------------|-----------|--|----|--|--|------|
|  | RL | 0,25 & 5 mg/ml  | 4°C       |  | 60 |  |  | 561  |
|  |    | 0,25 & 5 mg/ml  | -15°C     |  | 30 |  |  | 561  |
|  |    | 0,25 & 5 mg/ml  | 25°C      |  | 24 |  |  | 561  |
|  |    | 0,25 & 5 mg/ml  | 4°C       |  | 60 |  |  | 561  |
|  |    | 5 mg/ml         | 25°C      |  | 48 |  |  | 434  |
|  |    | 5 mg/ml         | 4°C       |  | 8  |  |  | 434  |
|  |    | 20 mg/ml        | -20°C     |  | 30 |  |  | 575  |
|  |    | 5 mg/ml         | 4°C       |  | 48 |  |  | 434  |
|  |    | 0,25 & 5 mg/ml  | 23°C      |  | 7  |  |  | 1816 |
|  |    | 0,25 & 5 mg/ml  | 4°C       |  | 30 |  |  | 1816 |
|  |    | 190 mg/ml       | 22°C-23°C |  | 48 |  |  | 639  |
|  |    | 0,25 & 20 mg/ml | 25°C      |  | 24 |  |  | 604  |
























































## Stabilité en mélange

|  |    | 5 mg/ml   | 23°C      |  | Cefpirome sulfate : 50 mg/ml       | 8  |  | 280 |
|--|----|-----------|-----------|--|------------------------------------|----|--|-----|
|  |    | 10 mg/ml  | 25°C      |  | Filgrastim : 40 µg/ml              | 4  |  | 104 |
|  | RL | 5 mg/ml   | 23°C      |  | Cefpirome sulfate : 50 mg/ml       | 8  |  | 280 |
|  |    | 5 mg/ml   | 23°C      |  | Cefpirome sulfate : 50 mg/ml       | 8  |  | 280 |
|  |    | 1,5 mg/ml | 25°C      |  | Ciprofloxacine lactate : 1,5 mg/ml | 48 |  | 434 |
|  |    | 4 mg/ml   | 25°C      |  | Clindamycine phosphate : 9 mg/ml   | 48 |  | 565 |
|  |    | 1,5 mg/ml | 4°C       |  | Ciprofloxacine lactate : 1,5 mg/ml | 48 |  | 434 |
|  |    | 190 mg/ml | 22°C-23°C |  | Clindamycine phosphate : 90 mg/ml  | 48 |  | 639 |



## Compatibilités

|  | Amikacine sulfate : 5 mg/ml<br>Aciclovir sodium : 5 mg/ml         | 336 |
|--|---|-----|
|  | Amikacine sulfate : 5 mg/ml<br>Allopurinol sodium : 3 mg/ml       | 307 |
|  | Amikacine sulfate : 5 mg/ml<br>Amifostine : 10 mg/ml              | 3   |
|  | Amikacine sulfate : 5 mg/ml<br>Amiodarone hydrochloride : 4 mg/ml | 385 |

|   |   |   |  |      |
|---|---|---|--|------|
|     |     | Amikacin sulfate<br>Amoxicillin sodium  |  | 3549 |
|    |    | Amikacin sulfate<br>Amoxicillin sodium  |  | 3527 |
|    |    | Amikacin sulfate<br>Amoxicillin sodium / clavulanic acid                              |  | 3545 |
|    |    | Amikacin sulfate<br>Amoxicillin sodium / clavulanic acid                              |  | 3549 |
|   |    | Amikacin sulfate : 250 mg/ml<br>Amoxicillin sodium / clavulanic acid : 100/10 mg/ml   |  | 3824 |
|    |    | Amikacin sulfate<br>Amphotericin B  |  | 3549 |
|    |    | Amikacin sulfate : 5 mg/ml<br>Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml |    | 921  |
|    |    | Amikacin sulfate<br>Ampicillin sodium   |  | 3549 |
|    |    | Amikacin sulfate<br>Ampicillin sodium - sulbactam sodium                              |  | 3549 |
|   |    | Amikacin sulfate : 5 mg/ml<br>Amsacrine : 1 mg/ml                                     |    | 253  |
|   |    | Amikacin sulfate : 5 mg/ml<br>Anidulafungin : 0.5 mg/ml                               |    | 1982 |
|    |    | Amikacin sulfate<br>Ascorbic acid   |  | 3549 |
|   |   | Amikacin sulfate : 100 mg/ml<br>Azithromycine : 2 mg/ml                               |   | 1800 |
|  |  | Amikacin sulfate<br>Aztreonam   |  | 3549 |
|   |  | Amikacin sulfate : 5 mg/ml<br>Aztreonam : 40 mg/ml                                    |  | 99   |
|   |  | Amikacin sulfate : 5 mg/ml<br>Bivalirudin : 5 mg/ml                                   |  | 1713 |
|   |  | Amikacin sulfate : 250 mg/ml<br>Caffeine : 10 mg/ml                                   |  | 3964 |
|  |  | Amikacin sulfate<br>Calcium gluconate   |  | 3644 |
|   |  | Amikacin sulfate : 5 mg/ml<br>Caspofungin acetate : 0,7 mg/ml                         |  | 2247 |
|  |  | Amikacin sulfate<br>Cefalotin sodium  |  | 3549 |
|  |  | Amikacin sulfate<br>Cefamandole nafate  |  | 3549 |
|  |  | Amikacin sulfate<br>Cefamandole nafate  |  | 3546 |
|  |  | Amikacin sulfate<br>Cefazolin sodium  |  | 3549 |
|  |  | Amikacin sulfate<br>Cefepime dihydrochloride  |  | 3549 |
|   |  | Amikacin sulfate : 15 mg/ml<br>Cefepime dihydrochloride : 125 mg/ml                   |  | 2141 |
|   |  | Amikacin sulfate : 6 mg/ml<br>Cefepime dihydrochloride : 40 mg/ml                     |  | 3548 |

|  |  |   |    |      |
|--|--|---|----|------|
|  |  | Amikacin sulfate : 5 mg/ml<br>Cefiderocol sulfate tosylate : 20 mg/mL |    | 4528 |
|  |  | Amikacin sulfate<br>Cefmenoxime                                       |    | 3549 |
|  |  | Amikacin sulfate<br>Cefmetazole sodium                                |    | 3549 |
|  |  | Amikacin sulfate<br>Cefonicid sodium                                  |    | 3549 |
|  |  | Amikacin sulfate<br>Cefoperazone sodium                               |    | 3549 |
|  |  | Amikacin sulfate<br>Cefoperazone sodium                               |    | 3544 |
|  |  | Amikacin sulfate<br>Ceforanide  |    | 3549 |
|  |  | Amikacin sulfate<br>Cefotaxime sodium                                 |    | 3549 |
|  |  | Amikacin sulfate<br>Cefoxitin sodium                                  |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Cefpirome sulfate : 50 mg/ml            |    | 280  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Cefpirome sulfate : 50 mg/ml            |    | 280  |
|  |  | Amikacin sulfate<br>Cefpirome sulfate                                 |    | 3677 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Cefpirome sulfate : 50 mg/ml            | RL | 280  |
|  |  | Amikacin sulfate<br>Cefpirome sulfate                                 |    | 3549 |
|  |  | Amikacin sulfate<br>Ceftaroline fosamil                               |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ceftaroline fosamil : 2,22 mg/ml        | RL | 3249 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ceftaroline fosamil : 2,22 mg/ml        |    | 3249 |
|  |  | Amikacin sulfate<br>Ceftazidime                                       |    | 3549 |
|  |  | Amikacin sulfate : 15 mg/ml<br>Ceftazidime : 83.3 mg/ml               |    | 1759 |
|  |  | Amikacin sulfate<br>Ceftazidime                                       |    | 3883 |
|  |  | Amikacin sulfate : 15 mg/ml<br>Ceftazidime : 125 mg/ml                |    | 2141 |
|  |  | Amikacin sulfate<br>Ceftazidime                                       |    | 3543 |
|  |  | Amikacin sulfate<br>Ceftazidime Avibactam                             |    | 3549 |
|  |  | Amikacin sulfate<br>Ceftizoxime sodium                                |    | 3549 |
|  |  | Amikacin sulfate<br>Ceftobiprole medocaril sodium                     |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ceftobiprole medocaril sodium : 2 mg/ml |    | 2269 |

|  |  |   |      |      |
|--|--|---|------|------|
|  |  | Amikacin sulfate : 5 mg/ml<br>Ceftobiprole medocartil sodium : 2 mg/ml  | RL   | 2269 |
|  |  | Amikacin sulfate<br>Ceftobiprole medocartil sodium                      |      | 4650 |
|  |  | Amikacin sulfate<br>Ceftolozane / tazobactam                            |      | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ceftolozane / tazobactam : 10/5 mg/ml     |      | 3828 |
|  |  | Amikacin sulfate<br>Ceftriaxone disodium                                |      | 3523 |
|  |  | Amikacin sulfate<br>Ceftriaxone disodium                                |      | 3549 |
|  |  | Amikacin sulfate<br>Cefuroxime sodium                                   |      | 3549 |
|  |  | Amikacin sulfate<br>Cefuroxime sodium                                   |      | 3687 |
|  |  | Amikacin sulfate<br>Cefuzonam   |      | 3549 |
|  |  | Amikacin sulfate<br>Chlorothiazide sodium                               |      | 3549 |
|  |  | Amikacin sulfate : 2.5 mg/ml<br>Cimetidine hydrochloride : 1.5 mg/ml    |      | 1201 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ciprofloxacin lactate : 2 mg/ml           |      | 285  |
|  |  | Amikacin sulfate : 4 mg/ml<br>Ciprofloxacin lactate : 1.5 mg/ml         |      | 434  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Cisatracurium besylate : 0.1 >> 5 mg/ml   |      | 299  |
|  |  | Amikacin sulfate<br>Cisplatin   |      | 3578 |
|  |  | Amikacin sulfate<br>Clindamycin phosphate                               |      | 3526 |
|  |  | Amikacin sulfate : 75 mg/ml<br>Clindamycin phosphate : 90 mg/ml         |      | 639  |
|  |  | Amikacin sulfate : 4 mg/ml<br>Clindamycin phosphate : 9 mg/ml           |      | 565  |
|  |  | Amikacin sulfate<br>Cloxacillin sodium                                  |      | 3549 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Cloxacillin sodium : 100 mg/ml          |      | 3012 |
|  |  | Amikacin sulfate<br>Cyanocobalamine                                     |      | 3549 |
|  |  | Amikacin sulfate<br>Daunorubicin/cytarabine liposomale : 0,4 mg/mL      |      | 4654 |
|  |  | Amikacin sulfate<br>Daunorubicin/cytarabine liposomale                  |      | 4354 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Defibrotide : 8 mg/ml                     |      | 3728 |
|  |  | Amikacin sulfate : 50 mg/ml<br>Dexamethasone sodium phosphate : 4 mg/ml | 0.45 | 132  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Dexmedetomidine : 4 µg/ml                 |      | 1712 |

|  |  |   |  |      |
|--|--|---|--|------|
|  |  | Amikacin sulfate : 5 & 250 mg/ml<br>Diltiazem hydrochloride : 5 mg/ml |  | 198  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Docetaxel : 0.9 mg/ml                   |  | 1754 |
|  |  | Amikacin sulfate<br>Doripenem   |  | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Doripenem : 5 mg/ml                     |  | 2262 |
|  |  | Amikacin sulfate : 2 mg/ml<br>Enalaprilate : 0.05 mg/ml               |  | 1315 |
|  |  | Amikacin sulfate<br>Ertapenem   |  | 3549 |
|  |  | Amikacin sulfate<br>Erythromycin lactobionate                         |  | 3674 |
|  |  | Amikacin sulfate<br>Erythromycin lactobionate                         |  | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Etoposide phosphate : 5 mg/ml           |  | 1410 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Fenoldopam mesylate : 80 µg/ml          |  | 1803 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Filgrastim : 40 µg/ml                   |  | 104  |
|  |  | Amikacin sulfate : 5 mg/ml  |  | 301  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Filgrastim : 30 µg/ml                   |  | 244  |
|  |  | Amikacin sulfate : 250 mg/ml  |  | 999  |
|  |  | Amikacin sulfate : 5 mg/ml  |  | 316  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Esmolol hydrochloride : 10 mg/ml        |  | 384  |
|  |  | Amikacin sulfate<br>Flucloxacillin sodium                             |  | 3522 |
|  |  | Amikacin sulfate : 0.487 >> 0.667 mg/ml                               |  | 1868 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Fosfomycin : 30 mg/ml                   |  | 4055 |
|  |  | Amikacin sulfate : 5 mg/ml  |  | 1415 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Fluconazole : 2 mg/ml                   |  | 256  |
|  |  | Amikacin sulfate : 20 mg/ml<br>Foscarnet sodium : 24 mg/ml            |  | 73   |
|  |  | Amikacin sulfate<br>Heparin sodium                                    |  | 3540 |
|  |  | Amikacin sulfate<br>Heparin sodium                                    |  | 1022 |
|  |  | Amikacin sulfate : 50 mg/ml   |  | 132  |
|  |  | Amikacin sulfate : 250 mg/ml  |  | 673  |
|  |  | Amikacin sulfate : 20 mg/ml<br>Fluconazole : 2 mg/ml                  |  | 496  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Gemcitabine hydrochloride : 10 mg/ml    |  | 1423 |

|  |  |   |    |      |
|--|--|---|----|------|
|  |  | Amikacin sulfate<br>Heparin sodium                                    |    | 3549 |
|  |  | Amikacin sulfate : 250 mg/ml  | RL | 4603 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Fludarabine phosphate : 1 mg/ml         |    | 492  |
|  |  | Amikacin sulfate : 2 mg/ml<br>Furosemide : 0,16 mg/ml                 |    | 367  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Granisetron hydrochloride : 0.05 mg/ml  |    | 182  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Hetastarch : 60 mg/ml                   |    | 1721 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Hetastarch : 60 mg/ml                   |    | 472  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Hydromorphone hydrochloride : 0.2 mg/ml |    | 405  |
|  |  | Amikacin sulfate : 250 mg/ml<br>Ibuprofen lysinate : 10 mg/ml         |    | 4419 |
|  |  | Amikacin sulfate : 50 mg/ml<br>Ibuprofen lysinate : 10 mg/ml          |    | 4419 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Idarubicin hydrochloride : 1 mg/ml      |    | 491  |
|  |  | Amikacin sulfate<br>Imipenem - cilastatin sodium                      |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Isavuconazonium sulfate : 1.5 mg/ml     |    | 3829 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Ketamine hydrochloride : 50 mg/ml     |    | 2109 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Labetalol hydrochloride : 1 mg/ml       |    | 386  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Lansoprazole : 0.55 mg/ml               |    | 1625 |
|  |  | Amikacin sulfate : 50 mg/ml<br>Levofloxacin : 5 mg/ml                 |    | 1072 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Linezolid : 2 mg/ml                     |    | 1925 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Lorazepam : 0.33 mg/ml                  |    | 186  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Magnesium sulfate : 16.67 >> 100 mg/ml  |    | 1047 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Melphalan : 0.1 mg/ml                   |    | 169  |
|  |  | Amikacin sulfate : 250 mg/ml<br>Meropenem : 50 mg/ml                  |    | 4319 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Meropenem : 50 mg/ml                  |    | 4389 |
|  |  | Amikacin sulfate<br>Meropenem   |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Metronidazole : 5 mg/ml                 |    | 1035 |
|  |  | Amikacin sulfate<br>Metronidazole                                     |    | 3594 |




|  |  |   |           |      |
|--|--|---|-----------|------|
|  |  | Amikacin sulfate : 5 mg/ml<br>Midazolam hydrochloride : 5 mg/ml           | ∅         | 186  |
|  |  | Amikacin sulfate : 5 mg/ml<br>Morphine sulfate : 1 mg/ml                  | ♦         | 405  |
|  |  | Amikacin sulfate : 250 mg/ml<br>N-acetylcysteine : 200 mg/ml              | ∅         | 3766 |
|  |  | Amikacin sulfate<br>Nafcillin sodium                                      |           | 3549 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Naloxone hydrochloride : 0.4 mg/ml        | ∅         | 3408 |
|  |  | Amikacin sulfate : 2 mg/ml<br>Nicardipine hydrochloride : 0.1 mg/ml       | ▲♦        | 1490 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Ondansetron hydrochloride : 1 mg/ml         | ▲         | 334  |
|  |  | Amikacin sulfate<br>Oxacillin sodium                                      |           | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Paclitaxel : 1.2 mg/ml                      | ♦         | 248  |
|  |  | Amikacin sulfate<br>Pantoprazole sodium                                   |           | 2090 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Paracetamol : 10 mg/ml                    |           | 4742 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Pemetrexed disodium : 20 mg/ml              | ▲         | 1953 |
|  |  | Amikacin sulfate<br>Penicillin G potassium                                |           | 3549 |
|  |  | Amikacin sulfate<br>Penicillin G sodium                                   |           | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Pethidine hydrochloride : 10 mg/ml          | ♦         | 405  |
|  |  | Amikacin sulfate : 50 mg/ml<br>Pethidine hydrochloride : 100 mg/ml        | ▲<br>0.45 | 132  |
|  |  | Amikacin sulfate<br>Phenytoin sodium                                      |           | 3549 |
|  |  | Amikacin sulfate : 40 mg/ml<br>Phloroglucinol : 2,5 mg/ml                 |           | 3791 |
|  |  | Amikacin sulfate<br>Piperacillin sodium                                   |           | 3549 |
|  |  | Amikacin sulfate<br>Piperacillin sodium / tazobactam                      |           | 3549 |
|  |  | Amikacin sulfate<br>Piperacillin sodium / tazobactam                      |           | 3586 |
|  |  | Amikacin sulfate<br>Posaconazole  |           | 4380 |
|  |  | Amikacin sulfate : 50 mg/ml<br>Propofol                                   |           | 4524 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Propofol : 10 mg/ml                         | ∅         | 300  |
|  |  | Amikacin sulfate<br>Pyridoxine hydrochloride                              |           | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Remifentanil hydrochloride : 25 & 250 µg/ml | ▲         | 59   |

|  |  |  |    |      |
|--|--|--|----|------|
|  |  | Amikacin sulfate : 250 mg/ml<br>Salbutamol sulfate : 1 mg/ml       | ∅  | 3216 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Sargramostim : 10 µg/ml              | ▲  | 335  |
|  |  | Amikacin sulfate : 10 mg/ml<br>Sulbactam/durlobactam : 15/15 mg/ml | ▲  | 4801 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Tedizolid phosphate : 0.8 mg/ml      | ▲  | 3827 |
|  |  | Amikacin sulfate<br>Teicoplanine                                   |    | 3656 |
|  |  | Amikacin sulfate<br>Temocilline                                    |    | 3549 |
|  |  | Amikacin sulfate<br>Temocilline                                    |    | 2296 |
|  |  | Amikacin sulfate : 15 mg/ml<br>Temocilline : 83.33 mg/ml           | 💧  | 2231 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Teniposide : 0.1 mg/ml               | ◆  | 905  |
|  |  | Amikacin sulfate<br>Thiamine hydrochloride                         |    | 3549 |
|  |  | Amikacin sulfate : 250 mg/ml<br>Thiopental sodium : 25 mg/ml       | ▲  | 3767 |
|  |  | Amikacin sulfate<br>Thiopental sodium                              |    | 3549 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Thiotepa : 1 mg/ml                   | ◆  | 249  |
|  |  | Amikacin sulfate<br>Ticarcillin / clavulanic acid                  |    | 3549 |
|  |  | Amikacin sulfate<br>Ticarcillin / clavulanic acid                  |    | 3587 |
|  |  | Amikacin sulfate<br>Tigecycline                                    | ▲  | 3332 |
|  |  | Amikacin sulfate : 15 mg/ml<br>Vancomycin hydrochloride : 10 mg/ml | ◆  | 3385 |
|  |  | Amikacin sulfate : 2 mg/ml<br>Verapamil hydrochloride : 0.08 mg/ml | ▲◆ | 1057 |
|  |  | Amikacin sulfate : 5 mg/ml<br>Vinorelbine tartrate : 1 mg/ml       | ▲  | 84   |
|  |  | Amikacin sulfate : 5 mg/ml<br>Warfarin sodium : 0.1 & 2 mg/ml      | ▲◆ | 552  |
|  |  | Amikacin sulfate : 4 mg/ml<br>Zidovudine : 4 mg/ml                 | ◆  | 337  |



## Voie d'administration





## Bibliographie

|     | Type  | Source  |
|-----|-------|---|
| 3   | Revue | Trissel LA, Martinez JF.<br>Compatibility of amifostine with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2208-2212.   |
| 59  | Revue | Trissel LA, Gilbert DL, Martinez JF, Kim MC.<br>Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 2192-2196.                   |
| 73  | Revue | Lor E, Takagi J.<br>Visual compatibility of foscarnet with other injectable drugs.<br>Am J Hosp Pharm 1990 ; 47: 157-159.   |
| 84  | Revue | Trissel LA, Martinez JF.<br>Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99  | Revue | Trissel LA, Martinez JF.<br>Compatibility of aztreonam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 1086-1090.  |
| 104 | Revue | Hall PD, Yui D, Lyons S, Bosso JA.<br>Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 185-189.                                 |
| 132 | Revue | Najari Z, Rusho WJ.<br>Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.<br>Am J Health-Syst Pharm 1997 ; 54: 181-184.  |
| 169 | Revue | Trissel LA, Martinez JF.<br>Physical compatibility of melphalan with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1993 ; 50: 2359-2363.  |
| 182 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 56-60.                                |
| 186 | Revue | Swart EL, Mooren RAG, Van Loenen AC.<br>Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1995 ; 52: 2020-2022.                |
| 198 | Revue | Gayed AA, Kheshary PR, Hinkle RL.<br>Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 516-520.                   |
| 244 | Revue | Trissel LA, Martinez JF.<br>Compatibility of filgrastim with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1907-1913.  |
| 248 | Revue | Trissel LA, Martinez JF.<br>Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1993 ; 50: 300-304.  |
| 249 | Revue | Trissel LA, Martinez JF.<br>Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1996 ; 53: 1041-1045.   |
| 253 | Revue | Trissel LA, Chandler SW, Folstad JT.<br>Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1990 ; 47: 2525-2528.   |

|     |       |  |
|-----|-------|--|
| 256 | Revue | Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.<br>Stability of fluconazole in commonly used intravenous antibiotic solutions.<br>Am J Hosp Pharm 1993 ; 50: 1206-1208.  |
| 280 | Revue | Allen LV, Stiles ML, Prince SJ, Sylvestri MF.<br>Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.<br>Am J Health-Syst Pharm 1995 ; 52: 2427-2433.             |
| 285 | Revue | Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.<br>Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.<br>Clin Ther 1996 ; 18: 246-255.   |
| 299 | Revue | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1735-1741.  |
| 300 | Revue | Trissel LA, Gilbert DL, Martinez JF.<br>Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1287-1292.                                    |
| 301 | Revue | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.<br>Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 | Revue | Trissel LA, Martinez JF.<br>Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1994 ; 51: 1792-1799.   |
| 316 | Revue | Veltri M, Lee CKK.<br>Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.<br>Am J Health-Syst Pharm 1996 ; 53: 2611-2613.   |
| 334 | Revue | Trissel LA, Tramonte SM, Grilley BJ.<br>Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 988-992.  |
| 335 | Revue | Trissel LA, Bready BB, Kwan JW, Santiago NM.<br>Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1992 ; 49: 402-406.  |
| 336 | Revue | Forman JK, Lachs JR, Souney PF.<br>Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1987 ; 44: 1408-1409.   |
| 337 | Revue | Bashaw ED, Amantea MA, Minor JR, Galleli JF.<br>Visual compatibility of zidovudine with other drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1988 ; 45: 2532-2533.   |
| 367 | Revue | Thompson DF, Allen LV, Desai SR, Rao PS.<br>Compatibility of furosemide with aminoglycoside admixtures.<br>Am J Hosp Pharm 1985 ; 42: 116-119.   |
| 384 | Revue | Colucci RD, Cobuzzi LE, Halpern NA.<br>Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 630-632.  |
| 385 | Revue | Benedict MK, Roche VF, Banakar UV, Hilleman DE.<br>Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 1117-1118.                    |
| 386 | Revue | Colucci RD, Cobuzzi LE, Halpern NA.<br>Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1988 ; 45: 1357-1358.                           |

|     |             |   |
|-----|-------------|---|
| 405 | Revue       | Nieves-Cordero AL, Luciw HM, Souney PF.<br>Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.<br>Am J Hosp Pharm 1985 ; 42: 1108-1109.   |
| 434 | Revue       | Goodwin SD, Nix DE, Heyd A, Wilton JH.<br>Compatibility of ciprofloxacin injection with selected drugs and solutions.<br>Am J Hosp Pharm 1991 ; 48: 2166-2171.  |
| 472 | Revue       | Wohlford JG, Fowler MD.<br>Visual compatibility of hetastarch with injectable critical-care drugs.<br>Am J Hosp Pharm 1989 ; 46: 995-996.   |
| 491 | Revue       | Turowski RC, Durthaler JM.<br>Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2181-2184.  |
| 492 | Revue       | Trissel LA, Parks NPT, Santiago NM.<br>Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.<br>Am J Hosp Pharm 1991 ; 48: 2186-2189.           |
| 496 | Revue       | Lor E, Sheybani T, Takagi J.<br>Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.<br>Am J Hosp Pharm 1991 ; 48: 744-746.  |
| 552 | Revue       | Martinez JF, Trissel LA, Gilbert DL.<br>Compatibility of warfarin sodium with selected drugs and large-volume parenteral solutions.<br>Int J Pharm Compound 1997 ; 1: 356-358.  |
| 561 | Revue       | Nunning BC, Granatek AP.<br>Physical compatibility and chemical stability of amikacin sulfate in large-volume parenteral solutions. Part II.<br>Current Ther Res 1976 ; 20: 359-368.  |
| 565 | Revue       | Marble DA, Bosso JA, Townsend RJ.<br>Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions.<br>Drug Intell Clin Pharm 1986 ; 20: 960-963. |
| 575 | Revue       | Holmes CJ, Ausman RK, Kundsinn RB, Walter CW.<br>Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags.<br>Am J Hosp Pharm 1982 ; 39: 104-108.   |
| 604 | Laboratoire | Stabilité des médicaments dans l'Intermate® SV50, 100, 200<br>Baxter 1998   |
| 639 | Revue       | Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ.<br>Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes.<br>Drug Intell Clin Pharm 1987 ; 21: 806-810.                       |
| 673 | Revue       | Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD.<br>The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures.<br>JPEN 1989 ; 13: 505-509.  |
| 905 | Revue       | Trissel LA, Martinez JF.<br>Screening teniposide for Y-site physical incompatibilities.<br>Hosp Pharm 1994 ; 29: 1010-1017.   |
| 921 | Revue       | Trissel LA, Gilbert DL, Martinez JF.<br>Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.<br>Hosp Pharm 1998 ; 33: 284-292.                     |
| 999 | Revue       | Watson D.<br>Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.<br>JPEN 1985 ; 9: 220-224.  |

|      |       |  |
|------|-------|--|
| 1022 | Revue | Hutchinson SMW.<br>Heparin and aminoglycosides instability.<br>Drug Intell Clin Pharm 1986 ; 20: 886.  |
| 1035 | Revue | Bisaillon S, Sarrazin R.<br>Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.<br>J Parenter Sci Technol 1983 ; 37: 129-132.  |
| 1047 | Revue | Souney PF, Colucci RD, Mariani G, Campbell D.<br>Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.<br>Am J Hosp Pharm 1984 ; 41: 323-324.                                       |
| 1057 | Revue | Cutie MR.<br>Compatibility of verapamil hydrochloride injection with commonly used additives.<br>Am J Hosp Pharm 1983 ; 40: 1205-1207.   |
| 1072 | Revue | Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.<br>Compatibility of levofloxacin with 34 medications during simulated Y-site administration.<br>Am J Health-Syst Pharm 1999 ; 56: 1458-1459.                                      |
| 1201 | Revue | Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.<br>Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.<br>Am J Hosp Pharm 1981 ; 38: 1919-1922.                                       |
| 1315 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R.<br>Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.<br>Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.      |
| 1410 | Revue | Trissel LA, Martinez JF, Simmons M.<br>Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 141-145.   |
| 1415 | Revue | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.<br>Compatibility of medications with 3-in-1 parenteral nutrition admixtures.<br>JPEN 1999 ; 23: 67-74.  |
| 1423 | Revue | Trissel LA, Martinez JF, Gilbert DL.<br>Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.<br>J Am Pharm Assoc 1999 ; 39: 514-518.  |
| 1490 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R.<br>The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.<br>Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1625 | Revue | Trissel LA, Saenz C, Williams YW, Ingram D.<br>Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2001 ; 5: 314-321.                                       |
| 1712 | Revue | Trissel LA, Saenz CA.<br>Compatibility screening of Precedex during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 230-233.   |
| 1713 | Revue | Trissel LA, Saenz CA.<br>Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2002 ; 6: 311-315.  |
| 1721 | Revue | Trissel LA, Williams KY, Baker MB.<br>Compatibility screening of Hextend during simulated Y-site administration with other drugs.<br>Int J Pharm Compound 2001 ; 5: 69-72.   |
| 1754 | Revue | Trissel LA, Gilbert DL, Wolkin AC.<br>Compatibility of docetaxel with selected drugs during simulated Y-site administration.<br>Int J Pharm Compound 1999 ; 3: 241-244.  |
| 1759 | Revue | Servais H, Tulkens PM.<br>Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.<br>Antimicrob Agents Chemother 2001 ; 45: 2643-2647.  |

|      |             |   |
|------|-------------|---|
| 1800 | Revue       | Voytilla KL, Tyler LS, Rusho WJ.<br>Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.<br>Am J Health-Syst Pharm 2002 ; 59: 853-855.  |
| 1803 | Revue       | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.<br>Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2003 ; 60: 80-85.  |
| 1816 | Revue       | Zhang Y, Trissel LA.<br>Stability of amikacin sulfate in autodose infusion system bags.<br>Int J Pharm Compound 2003 ; 7, 3: 230-232.   |
| 1868 | Revue       | Husson E, Crauste-Manciet S, Hadj-Salah E, Segier JC, Broissard D.<br>Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.<br>Nutr Clin Metab 2003 ; 17: 8-14.  |
| 1925 | Revue       | Trissel LA, Williams KY, Gilbert DL.<br>Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.<br>J Am Pharm Assoc 2000 ; 40: 515-519.  |
| 1953 | Revue       | Trissel LA, Saenz CA, Ogundele AB, Ingram DS.<br>Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2004 ; 61: 2289-2293.   |
| 1982 | Revue       | Trissel LA, Ogundele AB.<br>Compatibility of anidulafungin with other drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2005 ; 62: 834-837.   |
| 2090 | Revue       | Pere H, Chasse V, Forest JM, Hildgen P.<br>Compatibility of injectable pantoprazole in Y-site administration.<br>Pharmactuel 2004 ; 37: 193-196.  |
| 2109 | Revue       | Pelletier E, Forest JM, Hildgen P.<br>Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels.<br>Pharmactuel 2006 ; 39: 71-75.   |
| 2141 | Revue       | Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.<br>Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.<br>J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2231 | Revue       | de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.<br>Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.<br>J Antimicrob Chemother 2008 ; 61, 2: 382-388.                     |
| 2247 | Revue       | Chan P, Heatherly K, Kupiec T.C, Trissel L.A.<br>Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.<br>Int J Pharm Compound 2008 ; 12, 3: 276-278.   |
| 2262 | Revue       | Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D.<br>Compatibility of doripenem with other drugs during simulated Y-site administration<br>Am J Health-Syst Pharm 2008 ; 65: 1261-1265.   |
| 2269 | Revue       | Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.<br>Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.   |
| 2296 | Laboratoire | Témocilline (Negaban®) - Résumé des caractéristiques du produit<br>Eumedica 2017  |
| 3012 | Revue       | Sullivan T, Forrest J.M, Leclair G.<br>Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration<br>Hosp Pharm 2015 ; 50, 3: 214-220.  |

|      |             |  |
|------|-------------|--|
| 3216 | Revue       | Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.<br>Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.<br>Pharmactuel 2011 ; 44, 1 : 14-18                                      |
| 3249 | Revue       | Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.<br>Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3332 | Laboratoire | Tigecycline (Tigacyl®) - Summary of Product characteristics<br>Pfizer 2012   |
| 3385 | Revue       | Raverdi V, Ampe E, Hecq JD, Tulkens PM.<br>Stability and compatibility of vancomycin for administration by continuous infusion.<br>J Antimicrob Chemother 2013 ; 68: 1179-1182.  |
| 3408 | Revue       | Tollec S, Touzin K, Pelletier E, Forest J.M.<br>Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels.<br>Pharmactuel 2013 ; 46, 1 : 16-21.  |
| 3522 | Laboratoire | Flucloxacillin - Summary of Product Characteristics.<br>Actavis 2013   |
| 3523 | Laboratoire | Ceftriaxone (Rocephin®) - Summary of Product Characteristics.<br>Roche 2018  |
| 3526 | Laboratoire | Clindamycin (Dalacin®) - Summary of Product Characteristics<br>Pharmacia 2010  |
| 3527 | Laboratoire | Amoxicillin (Amoxil®) – Summary of Product Characteristics<br>Glaxo Smith Kline 2018   |
| 3540 | Laboratoire | Heparin sodium - Summary of Product Characteristics.<br>Wockhardt 2010   |
| 3543 | Laboratoire | Ceftazidime – Summary of Product Characteristics<br>Wockhardt 2013   |
| 3544 | Laboratoire | Cefoperazone (Cefobid®) - Summary of Product Characteristics<br>Pfizer 2006  |
| 3545 | Laboratoire | Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit<br>Mylan SAS 2009   |
| 3546 | Laboratoire | Cefamandole Flavelab - Résumé des caractéristiques du produit<br>Panpharma SA 2007   |
| 3548 | Laboratoire | Cefepime (Maxipime®) - Summary of Product characteristics.<br>Bristol Myers Squibb 2007  |
| 3549 | Laboratoire | Amikacine B Braun - Résumé des caractéristiques du produit.<br>B Braun 2012  |
| 3578 | Laboratoire | Cisplatine - Summary of Product Characteristics<br>Accord Healthcare 2011  |
| 3586 | Laboratoire | Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit<br>Actavis France 2010  |
| 3587 | Laboratoire | Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics<br>GlaxoSmithKline 2014   |
| 3594 | Laboratoire | Metronidazole (Flagyl®) - Summary of Product Characteristics<br>Zentiva 2013   |
| 3644 | Laboratoire | Calcium gluconate® - Summary of Product Characteristics<br>HameIn Pharmaceuticals 2010   |
| 3656 | Laboratoire | Teicoplanine (Targocid®) - Résumé des caractéristiques du produit<br>Sanofi Aventis France 2014  |
| 3674 | Laboratoire | Erythromycin lactobionate - Summary of Product Characteristics<br>PanPharma 2016   |
| 3677 | Laboratoire | Cefpirome (Cefrom®) - Résumé des caractéristiques du produit<br>Sanofi Aventis France 2008   |



|      |             |   |
|------|-------------|---|
| 3687 | Laboratoire | Cefuroxime sodium - Summary of Product Characteristics<br>Stravencon 2013   |
| 3728 | Revue       | Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.<br>Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2014 ; 71: 1288-1291.                                  |
| 3766 | Revue       | Forrest J.M, Hildgen P.<br>Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels<br>Pharmactuel 2014 ; 47, 3 : 161-165.   |
| 3767 | Revue       | Legris M.E, Lavoie A, Forrest J.M, Hildgen P.<br>Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.<br>Pharmactuel 2014 ; 47, 3 : 167-172.                               |
| 3791 | Poster      | Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.<br>Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.<br>Apifh Congress, Paris November 2014 2014              |
| 3824 | Revue       | Boudi S, Roy H, Forest JM, Leclair G.<br>Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.<br>Pharmactuel 2023 2023;56,3:91-98               |
| 3827 | Poster      | Ghazi I.M, Hamada Y, Nicolau D.P.<br>Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.<br>ASHP Midyear 2015   |
| 3828 | Poster      | Thabit A.K, Hamada Y, Nicolau D.P.<br>Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.<br>ASHP Midyear 2015  |
| 3829 | Poster      | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.<br>Compatibility of isavanazonium sulfate during simulated Y-site administration.<br>ASHP Midyear 2015  |
| 3883 | Laboratoire | Ceftazidime - Résumé des caractéristiques du produit<br>Arrow 2016  |
| 3964 | Revue       | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.<br>Pharmactuel 2017 ; 50,1 : 27-33.  |
| 4055 | Revue       | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.<br>Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2018 , 75, 1:36-44                           |
| 4319 | Revue       | Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.<br>Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.<br>Hosp Pharm 2020 ; 55, 5: 332-337.  |
| 4354 | Poster      | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.<br>Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.<br>GERPAC Congress 2019 2019                                 |
| 4380 | Laboratoire | Posaconazole (Noxafil®) - Summary of Product Characteristics<br>Merck Sharp & Dohme Limited 2019  |
| 4389 | Revue       | Côté K, Correard F, Metras M.E, Friciu M, Forest J.M, Leclair G.<br>Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédomidine, le lévamisole et la kétamine.<br>Pharmactuel 2019 ;52,4:206-213 |
| 4419 | Revue       | Holt R.J, Siegert S.W.K, Krishna A.<br>Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.<br>J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.   |

|      |             |   |
|------|-------------|---|
| 4524 | Poster      | Stucki C, Sautter A-M, Bonnabry P.<br>Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.<br>ESCP Symposium, Geneva, Switzerland 2009  |
| 4528 | Revue       | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.<br>Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.<br>Int J Pharm Compound 2021 ;25,1:52-61                                  |
| 4603 | Revue       | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.<br>Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.<br>Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4650 | Laboratoire | Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.<br>Advanz Pharma 2021   |
| 4654 | Poster      | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.<br>Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.<br>Communication personnelle 2021                         |
| 4742 | Revue       | Macoviciuc M, Nguyen C, Forest J-M, Leclair G.<br>Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y.<br>Pharmactuel 2022 ; 55, 4: 247-255.                                       |
| 4801 | Revue       | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.<br>Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.<br>Am J Health-Syst Pharm 2024 ;51,1:                |



# Dictionnaire

|   |  |
|---|--|
|  Antibiotique                              |  Injectable                                 |
|  Noms commerciaux                          |  Stabilité des solutions                    |
|  Contenant                                 |  Molécule                                   |
|  Concentration                             |  Température                                |
|  Conservation                              |  Durée de stabilité                         |
|  Biosimilaire                              |  Données conflictuelles                     |
|  Bibliographie                             |  Verre                                      |
|  NaCl 0,9% ou glucose 5%                   |  A l'abri de la lumière                     |
|  Jour                                      |  Non précisée                               |
|  Heure                                     | <b>RL</b> Ringer lactate   |
|  Chlorure de sodium 0,45%                  |  Polyvinyl chlorure                         |
|  Lumière                                   |  Chlorure de sodium 0,9%                    |
|  Glucose 5%                               |  Ethylène vinyl acétate                    |
|  Seringue polypropylène                  |  Elastomère en polyisoprène               |
|  Stabilité en mélange                    |  Solvant                                  |
|  Molécule                                |  Compatibilités                           |
|  Compatible                              |  Précipitation en 1 heure                 |
|  Incompatible                            |  Instabilité chimique                     |
|  Incompatibilité non précisée            |  Précipitation immédiate                  |
|  Aucun                                   |  Eau pour préparation injectable          |
|  Incompatibilité subvisuelle             |  Turbidité immédiate                      |
|  Nutrition parentérale (mélange binaire) |  Nutrition parentérale (mélange ternaire) |
|  Instabilité de l'émulsion immédiate     |  Instabilité de l'émulsion en 1 heure     |
|  Solvant spécifique                      |  Voie d'administration                    |
|  Intraveineuse                           |  Perfusion intraveineuse                  |
|  Intramusculaire                         |  Sous cutanée                             |
|  Intrathécale                            |  Perfusion sous-cutanée                   |
|  Bibliographie                           |  Dictionnaire                             |